Understanding the mechanism of the antimitogenic activity of suramin

Biochemistry

Volumn 45, Issue 3, 2006, Pages 899-906

  Kathir, Karuppanan Muthusamy ^a   Kumar, Thallapuranam Krishnaswamy S ^a   Yu, Chin ^a,b  

^a UNIVERSITY OF ARKANSAS   (United States)

^b NATIONAL TSING HUA UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CALORIMETRY; ISOTHERMS; SIZE EXCLUSION CHROMATOGRAPHY; STOICHIOMETRY; TITRATION; TUMORS;

ANTIMITOGENIC ACTIVITY; FIBROBLAST GROWTH FACTORS (FGFS); NANOMOLAR RANGE; SURAMIN;

CELLS;

ANTIMITOTIC AGENT; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 1; HEPARIN; SURAMIN; TRYPSIN;

ANGIOGENESIS; ARTICLE; BINDING SITE; CELL DIFFERENTIATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; FLUORESCENCE; GEL PERMEATION CHROMATOGRAPHY; ISOTHERMAL TITRATION CALORIMETRY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OLIGOMERIZATION; PRIORITY JOURNAL; STEADY STATE; STOICHIOMETRY; TUMOR GROWTH;

ANTIMITOTIC AGENTS; ESCHERICHIA COLI; FIBROBLAST GROWTH FACTOR 1; HUMANS; MITOSIS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN CONFORMATION; PROTEIN FOLDING; SURAMIN;

EID: 31044435080     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi051389b     Document Type: Article

References (34)

1. Cao, Y. (2004) Antiangiogenic cancer therapy, Semin. Cancer Biol. 14, 139-145.
2. Burgess, W. H., and Maciag, T. (1989) The heparin-binding (fibroblast) growth factor family of proteins, Annu. Rev. Biochem. 58, 575-606.
3. Folkman, J., and Klagsburn, M. (1987) Angiogenic factors, Science 235, 442-447.
4. Manetti, F., Corelli, F., and Botta, M. (2000) Fibroblast growth factors and their inhibitors, Curr. Pharm. Des. 6, 1897-1924.
5. Sola, F. L., Capolonga, D., Moneta, P., Ubezio, P., and Grandi, M. (1999) Cancer Chemother. Pharmacol. 36, 217-222.
6. Zamai, M., Hariharan, C., Pines, D., Safran, M., Yayon, A., Caiolfa, V. R., Cohen-Luria, R., Pines, E., and Parola, A. H. (2002) Nature of interaction between basic fibroblast growth factor and the antiangiogenic drug 7,7-(carbonyl-bis[imino-N-methyl-4,2-pyrrolecarbonylimino[N-methyl-4,2-pyrrole] -carbonylimino])-bis-(1,3-naphthalene disulfonate). II. Removal of polar interactions affects protein folding, Biophys. J. 82, 2652-2664.
7. Song, S., Wientjes, M. G., Gan, Y., and Au, J. L. S. (2000) Fibroblast growth factors: An epigenetic mechanism of broad spectrum resistance to anticancer drugs, Proc. Natl. Acad. Sci. U.S.A. 97, 8658-8663.
8. Middaugh, C. R., Mach, H., Burke, C. J., Volkin, D. B., Dabora, J. M., Tsu, P. K., Brunner, M. W., Ryan, J. A., and Marfia, K. E. (1992) Nature of the interaction of growth factors with suramin, Biochemistry 31, 9016-9024.
9. Lozano, R. M., Jimenez, M. A., Santora, J., Rico, M., and Gallego, G. G. (1998) Solution structure of acidic fibroblast growth factor bound to 1,3,6-naphthalenetrisulfonate: A minimal model for the anti-tumoral action of suramins and suradistas, J. Mol. Biol. 281, 899-915.
10. Arunkumar, A. I., Kumar, T. K., Kathir, K. M., Srisailam, S., Wang, H. M., Leena, P. S., Chi, Y. H., Chen, H. C., Wu, C. H., Wu, R. T., Chang, G. G., Chiu, I. M., and Yu, C. (2002) Oligomerization of acidic fibroblast growth factor is not a prerequisite for its cell proliferation activity, Protein Sci. 11, 1050-1061.
11. Chi, Y. H., Kumar, T. K. S., Kathir, K. M., Lin, D. H., Zhu, G., Chiu, I. M., and Yu, C. (2002) Investigation of the structural stability of the human acidic fibroblast growth factor by hydrogen-deuterium exchange, Biochemistry 41, 15350-15339.
12. Ogura, K. K., Nagata, H., Hatanaka, H., Habuchi, K., Kimata, S., Tata, S., Raveral, M. W., Jaye, J., Schlessinger, J., and Inagaki, F. (1999) Solution structure of human acidic fibroblast growth factor and interaction with heparin-derived hexasaccharide, J. Biomol. NMR 13, 11-24.
13. Arunkumar, A. I., Srisailam, S., Kumar, T. K., Kathir, K. M., Chi, Y. H., Wang, H. M., Chang, G. G., Chiu, I., and Yu, C. (2002) Structure and stability of an acidic fibroblast growth factor from Notophthalmus viridescens, J. Biol. Chem. 277, 46424-46432.
14. Schlessinger, J. (2004) Common and distinct elements in cellular signaling via EGF and FGF receptors, Science 306, 1506-1507.
15. Plotnikov, A. N., Hubbard, S. R., Schlessinger, J., and Mohammadi, M. (2000) Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity, Cell 101, 413-424.
16. Pellegrini, L. (2001) Role of heparan sulfate in fibroblast growth factor signalling: A structural view, Curr. Opin. Struct. Biol. 11, 629-634.
17. Hung, K. W., Kumar, T. K., Chi, Y. H., Chiu, I. M., and Yu, C. (2004) Molecular cloning, overexpression, and characterization of the ligand-binding D2 domain of fibroblast growth factor receptor, Biochem. Biophys. Res. Commun. 317, 253-258.
18. Schlessinger, J., Plotnikov, A. N., Ibrahimi, O. A., Eliseenkova, A. V., Yeh, B. K., Yayon, A., Linhardt, R. J., and Mohammadi, M. (2000) Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization, Mol. Cell 6, 743-750.
19. Yeh, B. K., Eliseenkova, A. V., Plotnikov, A. N., Green, D., Pinnell, J., Polat, T., Gritli-Linde, A., Linhardt, R. J., and Mohammadi, M. (2002) Structural basis for activation of fibroblast growth factor signaling by sucrose octasulfate, Mol. Cell. Biol. 22, 7184-7192.
20. Pantoliano, M. W., Horlick, R. A., Springer, B. A., Van Dyk, D. E., Tobery, T., Wetmore, D. R., Lear, J. D., Nahapetian, A. T., Bradley, J. D., and Sisk, W. P. (1994) Multivalent ligand-receptor binding interactions in the fibroblast growth factor system produce a cooperative growth factor and heparin mechanism for receptor dimerization, Biochemistry 33, 10229-10248.
21. Wang, L., Li, J. J., Zheng, Z. B., Liu, H. X., Du, G. J., and Li, S. (2004) Antitumor activities of a novel indolin-2-ketone compound, Z24: More potent inhibition on bFGF-induced angiogenesis and bcl-2 over-expressing cancer cells, Eur. J. Pharmacol. 502, 1-10.
22. Zhao, L., Wientjes, M. G., and Au, A. L. (2004) Evaluation of combination chemotherapy: Integration of nonlinear regression, curve shift, isobologram, and combination index analyses, Clin. Cancer Res. 10, 7994-8004.
23. Song, S., Yu, B., Wei, Y., Wientjes, M. G., and Au, J. L. (2004) Low-Dose Suramin Enhanced Paclitaxel Activity in Chemotherapy-Naïve and Paclitaxel-retreated Human Breast Xenograft Tumors, Clin. Cancer Res. 10, 6058-6065.
24. Brown, P. H., and Beckett, D. (2005) Use of inding enthalpy to drive an allosteric transition, Biochemistry 44, 3112-3121.
25. Banerjee, M., Poddar, A., Mitra, G., Surolea, A., Owa, T., and Battacharyya, B. (2005) Sulfonamide drugs binding to the colchicine site of tubulin: Thermodynamic analysis of the drug-tubulin interactions by isothermal titration calorimetry, J. Med. Chem. 48, 547-555.
26. Selwood, T., Smolensky, H., McCaslin, D. R., and Schechter, N. M. (2005) The interaction of human tryptase-β with small molecule inhibitors provides new insights into the unusual functional instability and quaternary structure of the protease, Biochemistry 44, 3580-3590.
27. Weisshart, K., Friedl, S., Taneja, P., Nasheuer, H. P., Schlott, B., Grosse, F., and Fanning, E. (2004) Partial Proteolysis of Simian Virus 40 T Antigen Reveals Intramolecular Contacts between Domains and Conformation Changes upon Hexamer Assembly, J. Biol. Chem. 279, 38943-38951.
28. Hajduk, P. J., Meadows, R. P., and Fesik, S. W. (1999) NMR-based screening in drug discovery, Q. Rev. Biophys. 32, 211-240.
29. Yu, L., Oost, T. K., Schkerjantz, J. M., Yang, J., Janowick, D., and Fesik, S. W. (2003) Discovery of aminoglycoside mimetics by NMR-based screening of Escherichia coli A-site RNA, J. Am. Chem. Soc. 125, 4444-4450.
30. Zuiderweg, E. R. (2002) Mapping protein-protein interactions in solution by NMR spectroscopy, Biochemistry 41, 1-7.
31. Pellegrini, L., Burke, D. F., von Delft, F., Mulloy, B., and Blundell, T. L. (2000) Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin, Nature 407, 1029-1034.
32. Schlessinger, J., Plotnikov, A. N., Ibrahimi, O. A., Eliseenkova, A. V., Yeh, B. K., Yayon, A., Linhardt, R. J., and Mohammadi, M. (2000) Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization, Mol. Cell 6, 743-750.
33. Fernandez-Tornero, C., Lozano, R. M., Redondo-Horcajo, M., Gomez, A. M., Lopez, J. C., Quesada, E., Uriel, C., Valverde, S., Cuevas, P., Romero, A., and Gimenez-Gallego, G. (2003) Leads for development of new naphthalenesulfonate derivatives with enhanced antiangiogenic activity: Crystal structure of acidic fibroblast growth factor in complex with 5-amino-2-naphthalene sulfonate, J. Biol. Chem. 278, 21774-21781.
34. Manetti, F., Cappello, V., Botta, M., Corelli, F., Mongelli, N., Biasoli, G., Borgia, A. L., and Ciomei, M. (1998) Synthesis and binding mode of heterocyclic analogues of suramin inhibiting the human basic fibroblast growth factor, Bioorg. Med. Chem. 6, 947-958.